REGENXBIO (NASDAQ:RGNX – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Analyst Recommendations
This is a summary of current ratings and price targets for REGENXBIO and Dermata Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| REGENXBIO | 1 | 1 | 9 | 0 | 2.73 |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
REGENXBIO presently has a consensus target price of $23.91, indicating a potential upside of 278.91%. Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 713.01%. Given Dermata Therapeutics’ higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than REGENXBIO.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| REGENXBIO | $87.82 million | 3.71 | -$193.88 million | ($5.60) | -1.13 |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($5.31) | -0.23 |
Dermata Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares REGENXBIO and Dermata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| REGENXBIO | -330.23% | -232.50% | -61.02% |
| Dermata Therapeutics | N/A | -127.91% | -105.05% |
Risk & Volatility
REGENXBIO has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Summary
Dermata Therapeutics beats REGENXBIO on 7 of the 13 factors compared between the two stocks.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
